The new phase 3 trial, in first-line CLL, is expected to begin in January 2026.
ApexOnco Front Page
Recent articles
Ideate-Lung02 goes on global clinical hold.
Harmoni-6 succeeds in first-line lung cancer, but the focus is on changes to Harmoni-3.
After promising early data in head and neck, J&J plans a new phase 3, Origami-5.
Full data from Edge-Gastric are presented at ESMO.
The first TUB-040 data come just after Tubulis raised €308m.
But the ESMO discussant recommends against widespread use in hormone-sensitive disease.
Both are heralded as a new first-line standard of care, but Datroway seems to have the edge.
